Inventor · disambiguated record
Jan Wasley
Also filed as: WASLEY JAN · WASLEY JAN W · WASLEY JAN W F
33 granted patents·2 pending applications·175 citations·filing 1995–2016
97Inventor score
Files withNEUROGEN CORP14N30 PHARMACEUTICALS INC8WASLEY JAN4NIVALIS THERAPEUTICS INC3HELICON THERAPEUTICS INC2
Top patents by PatentIndex Score
35 records- 0190US8691816B2Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agentsWASLEY JAN·Filed 2009·Granted Apr 8, 2014·11 cites·28 claims
- 0290US8470857B2Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agentsWASLEY JAN·Filed 2009·Granted Jun 25, 2013·13 cites·7 claims
- 0388US8673961B2Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agentsWASLEY JAN·Filed 2009·Granted Mar 18, 2014·7 cites·17 claims
- 0487US8481590B2Chromone inhibitors of S-nitrosoglutathione reductaseSUN XICHENG·Filed 2010·Granted Jul 9, 2013·8 cites·6 claims
- 0586US9180119B2Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agentsN30 PHARMACEUTICALS INC·Filed 2015·Granted Nov 10, 2015·4 cites·19 claims
- 0686US8957105B2Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agentsN30 PHARMACEUTICALS INC·Filed 2014·Granted Feb 17, 2015·5 cites·19 claims
- 0786US8686015B2Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agentsN30 PHARMACEUTICALS INC·Filed 2013·Granted Apr 1, 2014·7 cites·8 claims
- 0886US8642628B2Pyrrole inhibitors of S-nitrosoglutathione reductaseWASLEY JAN·Filed 2009·Granted Feb 4, 2014·8 cites·8 claims
- 0985US9138427B2Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agentsN30 PHARMACEUTICALS INC·Filed 2014·Granted Sep 22, 2015·5 cites·19 claims
- 1084US8846736B2Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agentsN30 PHARMACEUTICALS INC·Filed 2014·Granted Sep 30, 2014·5 cites·8 claims
- 1184US8669381B2Chromone inhibitors of S-nitrosoglutathione reductaseN30 PHARMACEUTICALS INC·Filed 2013·Granted Mar 11, 2014·5 cites·10 claims
- 1283US7872002B2Therapeutic pyrazoloquinoline derivativesHELICON THERAPEUTICS INC·Filed 2008·Granted Jan 18, 2011·6 cites·40 claims
- 1383US6245768B11-(N′-(arylalkylaminoalkyl)) aminoisoindoles; a new class of dopamine receptor subtype specific ligandsNEUROGEN CORP·Filed 1999·Granted Jun 12, 2001·31 cites·8 claims
- 1480US9029402B2Pyrrole inhibitors of S-nitrosoglutathione reductaseN30 PHARMACEUTICALS INC·Filed 2014·Granted May 12, 2015·4 cites·11 claims
- 1576US7858614B2Therapeutic pyrazolonaphthyridine derivativesHELICON THERAPEUTICS INC·Filed 2008·Granted Dec 28, 2010·2 cites·26 claims
- 1675US9498466B2Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agentsNIVALIS THERAPEUTICS INC·Filed 2015·Granted Nov 22, 2016·1 cites·11 claims
- 1768US6384224B2Certain 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl) piperazines; dopamine receptor subtype specific ligandsNEUROGEN CORP·Filed 2001·Granted May 7, 2002·3 cites·7 claims
- 1868US6040448ACertain 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl) piperazines, dopamine receptor subtype specific ligandsNEUROGEN CORP·Filed 1998·Granted Mar 21, 2000·10 cites·23 claims
- 1967US6331629B1Certain 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl)piperazines; dopamine receptor subtype specific ligandsNEUROGEN CORP·Filed 2000·Granted Dec 18, 2001·3 cites·13 claims
- 2063US9814700B2Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agentsNIVALIS THERAPEUTICS INC·Filed 2016·Granted Nov 14, 2017·0 cites·21 claims
- 2163US5602168A1-(N'-(arylalkylaminoalkyl)) aminoisoindoles; dopamine receptor subtype specific ligandsNEUROGEN CORP·Filed 1995·Granted Feb 11, 1997·9 cites·7 claims
- 2260US2014163092A1Chromone Inhibitors of S-Nitrosoglutathione ReductaseN30 PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2359US6031097A1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligandsNEUROGEN CORP·Filed 1998·Granted Feb 29, 2000·5 cites·26 claims
- 2459US5744472A1-(N'-(arylalkylaminoalkyl)) aminoisoindoles; a new class of dopamine receptor subtype specific ligandsNEUROGEN CORP·Filed 1995·Granted Apr 28, 1998·7 cites·6 claims
- 2559US5656632A1-(N'-(arylalkylaminoalkyl)) aminoisoindoles; dopamine receptor subtype specific ligandsNEUROGEN CORP·Filed 1995·Granted Aug 12, 1997·6 cites·14 claims
- 2656US9717706B2Chromone inhibitors of S-nitrosoglutathione reductaseNIVALIS THERAPEUTICS INC·Filed 2015·Granted Aug 1, 2017·0 cites·12 claims
- 2756US2005124701A1Method of targeting a therapeutic agentFiled 2004·Application pending·0 cites
- 2852US5760234ACertain 1-substituted aminomethyl imidazole and pyrrole derivatives: novel dopamine receptor subtype specific ligandsNEUROGEN CORP·Filed 1995·Granted Jun 2, 1998·3 cites·8 claims
- 2951US5932729A1-(N'-(arylalkylaminoalkyl)) aminoisoindoles; a new class of dopamine receptor subtype specific ligandsNEUROGEN CORP·Filed 1997·Granted Aug 3, 1999·3 cites·1 claims
- 3049US6441175B11-(N'-arylalkylaminoalkyl)aminoisoquinolines: a new class of dopamine receptor subtypeNEUROGEN CORP·Filed 2001·Granted Aug 27, 2002·0 cites·4 claims
- 3147US5750700ACertain 1-substituted aminomethyl imidazole and pyrrole derivatives: novel dopamine receptor subtype specific ligandsNEUROGEN CORP·Filed 1995·Granted May 12, 1998·2 cites·2 claims
- 3246US8598159B2Therapeutic pyrazoloquinoline derivativesKAPLAN ALAN P·Filed 2010·Granted Dec 3, 2013·0 cites·7 claims
- 3346US8497262B2Therapeutic pyrazolonaphthyridine derivativesKAPLAN ALAN P·Filed 2010·Granted Jul 30, 2013·0 cites·7 claims
- 3441US6252077B11-(N′-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligandsNEUROGEN CORP·Filed 1999·Granted Jun 26, 2001·1 cites·2 claims
- 3539US6002005ACertain 1-substituted aminomethyl imidazole and pyrrole derivatives: novel dopamine receptor subtype specific ligandsNEUROGEN CORP·Filed 1998·Granted Dec 14, 1999·1 cites·5 claims
Join the waitlist — get patent alerts
Get an alert when Jan Wasley files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →